Accessibility statement

What's wrong with economic evaluations for cancer drug funding decisions in Canada (and how to fix it)

Thursday 10 June 2010, 1.15PM to 3.00pm

Speaker(s): Jeffrey Hoch, Director of the Pharmacoeconomics Research Unit, Cancer Care Ontario; Associate Professor of Health Economics, University of Toronto, Canada.

The purpose of this research is to understand the limitations of economic evaluation studies submitted to the interim Joint Oncology Drug Review (JODR) to inform oncology drug reimbursement decisions in Canada.  We reviewed the pharmacoeconomic reviewers' comments on all submissions to Canada's JODR, extracting comments related to limitations of the analysis.  This talk will present the results and discuss their implications.

Location: ARRC Auditorium

Who to contact

For more information on these seminars, contact:

Adriana Castelli 
Tel: +44 (0)1904 321462
Eamil: ac52@york.ac.uk  

CHE Seminar Programme

  • Thursday, 2nd December  
    Hans Severens, Professor of Evaluation in Health Care at Erasmus University, Rotterdam, Netherlands
  • Monday, 10th January
    Hugh Gravelle, Professor of Health Economics, Centre for Health Economics, University of York
  • Thursday, 3rd March
    Alistair McGuire, Professor, Department of Social Policy & LSE Health, London School of Economics